A New York-based biopharmaceutical company has received a grant from Cure Parkinson’s to initiate a phase 2 clinical trial investigating dapansutrile, an oral small molecule, as a disease-modifying therapy for Parkinson’s disease.
According to a release from Olatec Therapeutics, the investigator-initiated study is expected to enroll 36 individuals in the early stages of PD. Patients will be treated for 6 months with either dapansutrile or placebo, followed by an optional 6-month open-label phase.
The trial will be conducted at the John van Geest Centre for Brain Repair in the